Anzeige
Erschienen in:
01.09.2009 | Original Article
The effectiveness of FloSeal® matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study
Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2009
Einloggen, um Zugang zu erhaltenAbstract
Background
The objective of this study was to compare the effectiveness of FloSeal® matrix hemostatic agent with hemostatic surgical procedures and Tabotamp® in thyroid surgery.
Methods
One hundred fifty-five consecutive total thyroidectomy patients were recruited at our institution between January 2005 and December 2007. Exclusion criteria were applied. Patients were randomized to one of three hemostatic approaches: 49 received surgical procedures only, and 52 received oxidized regenerated cellulose patch (Tabotamp Fibrillar 2.5 × 5 cm) and 54 FloSeal (5,000 U/5 mL). The same surgeon performed all operations.
Results
Mean operating time was reduced in the FloSeal group (105 min) vs. surgical (133 min, p = 0.02) and vs. Tabotamp (122 min, p = 0.0003). Also, wound drain removal occurred earlier with FloSeal (p = 0.006 vs. surgical; p = 0.008 vs. Tabotamp) resulting in shorter postoperative hospital stay in the FloSeal group (p = 0.02 vs. surgical; p = 0.002 vs. Tabotamp).
Conclusions
FloSeal matrix is an effective additional agent to conventional haemostatic procedures in thyroid surgery.